Department of Pharmaceuticals mandates self-declaration for compliance with new Uniform Code for Pharmaceutical Marketing Practices (UCPMP) by 30th June, 2024

Department of Pharmaceuticals mandates self-declaration for compliance with new Uniform Code for Pharmaceutical Marketing Practices (UCPMP) by 30th June, 2024

Department of Pharmaceuticals mandates self-declaration for compliance with new Uniform Code for Pharmaceutical Marketing Practices (UCPMP) by 30th June, 2024

by Lexplosion | Jun 4, 2024 | Central, OPS, Pharmaceuticals

The Department of Pharmaceuticals has directed pharmaceutical companies to submit self-declaration... Read More

Stakeholders in medical devices sector urged by CDSCO to ensure timely payment of retention fees to maintain validity of licenses and certificates

Stakeholders in medical devices sector urged by CDSCO to ensure timely payment of retention fees to maintain validity of licenses and certificates

by Lexplosion | May 31, 2024 | Central, OPS, Pharmaceuticals

The Central Drugs Standard Control Organisation (“CDSCO”) has reiterated that licenses for... Read More

CDSCO allows operational continuity for importers and manufacturers of Class C & D Medical Devices; pending pre-September 2023 licensing applications deemed valid until 16th August, 2024 or CLA decision

CDSCO allows operational continuity for importers and manufacturers of Class C & D Medical Devices; pending pre-September 2023 licensing applications deemed valid until 16th August, 2024 or CLA decision

by Lexplosion | May 21, 2024 | Central, OPS, Pharmaceuticals

The Central Drugs Standard Control Organization (CDSCO) has issued a Circular in response to... Read More

CDSCO mandates online submission of Period Safety Update Reports (PSURs) through Sugam Portal, offline submissions to be discontinued from 11th March, 2024

CDSCO mandates online submission of Period Safety Update Reports (PSURs) through Sugam Portal, offline submissions to be discontinued from 11th March, 2024

by Lexplosion Solution | Feb 29, 2024 | Central, OPS, Pharmaceuticals

With a view to streamline the regulatory submission procedure, the Central Drugs Standards Control... Read More

Health Ministry permits the sale of Oseltamivir Phosphate and Zanamivir akin to Schedule H1 drugs, with restrictions on sale and export regulated by the Government and DCGI

Health Ministry permits the sale of Oseltamivir Phosphate and Zanamivir akin to Schedule H1 drugs, with restrictions on sale and export regulated by the Government and DCGI

by Lexplosion Solution | Feb 12, 2024 | Central, OPS, Pharmaceuticals

Ministry of Health and Family Welfare has issued a Notification dated February 5, 2024, revoking... Read More

« Older Entries

Next Entries »